Hospital Statistics 1 April 2001 - 31 March 2002

Volume 1: Programme of Care

Hospital Statistics 1 April 2000 - 31 March 2001

Volume 1: Programme of Care

Northern Ireland Community Statistics (PDF 31 KB)

1999/2000 to 2003/2004 - Key Facts

Hospital Statistics 1 April 1999 - 31 March 2000

Volume 1: Programme of Care

Hospital Statistics 1 April 1998 - 31 March 1999

Volume 1: Programme of Care

Health Statistics 2002

The four key principles guiding the development of the Health Strategy (2001): Quality and Fairness: A Health System for You are equity, people-centredness, quality and accountability. High quality statistical data are fundamental to the delivery of each of these. Relevant, accurate and accessible information should inform all health decisions. This includes information for the public as well as data required to enable evidence-based service delivery and evaluation, policy formulation and the measurement of health gain.This compendium of health statistics brings together data from a wide variety of sources on demography, health status and the delivery of health services. It provides a broad overview of health in Ireland as well as serving as a resource and reference for those interested in particular aspects of health and the health services. Download document here

Older People in Ireland A Profile of Health Status, Lifestyle and Socio-Economic Factors from SLÃÅN

Click here to download PDF

Health Statistics 1999

10.6.1999 This compendium of health statistics brings together data from a wide variety of sources on demographics, health and health service utilisation. It has been extensively revised and expanded compared with earlier editions. The intention is to provide a statistical overview as well as serving as a resource and reference for those interested in particular aspects of health Download the Report here

Report on Perinatal Statistics for 2002

Click here to download PDF

Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.

Crizotinib is a first-in-class oral anaplastic lymphoma kinase (ALK) inhibitor targeting ALK-rearranged non-small-cell lung cancer. The therapy was approved by the US FDA in August 2011 and received conditional marketing approval by the European Commission in October 2012 for advanced non-small-cell lung cancer. A break-apart FISH-based assay was jointly approved with crizotinib by the FDA. This assay and an immunohistochemistry assay that uses a D5F3 rabbit monoclonal primary antibody were also approved for marketing in Europe in October 2012. While ALK rearrangement has relatively low prevalence, a clinical benefit is exhibited in more than 85% of patients with median progression-free survival of 8-10 months. In this article, the authors summarize the therapy and alternative test strategies for identifying patients who are likely to respond to therapy, including key issues for effective and efficient testing. The key economic considerations regarding the joint companion diagnostic and therapy are also presented. Given the observed clinical benefit and relatively high cost of crizotinib therapy, companion diagnostics should be evaluated relative to response to therapy versus correlation alone whenever possible, and both high inter-rater reliability and external quality assessment programs are warranted.

Long-Stay Activity Statistics 2012

This report presents data collected through a survey of long-stay units in 2012. The aim of the survey is to provide statistics on the number of beds available for long-term care, how the beds are used and the types of patients who occupy these beds.In order to present the data this report has been divided into a number of sections. This introductory section examines how data was collected and analysed and gives a summary of the results. Long-Stay Activity Statistics 2012